Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo shows promise for kids with brain cancer

NCT ID NCT05081180

Ongoing Disease control Sponsor: EMD Serono Research & Development Institute, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing two drugs, avelumab and lenvatinib, together in children with brain tumors that have not responded to prior treatment. The study has two parts: first, finding a safe dose, and second, seeing if the combination can slow tumor growth. Only 17 children are enrolled, so results are very preliminary.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
avelumab and lenvatinib
What this could lead to
If this works, it could point toward a new treatment option for children with hard-to-treat brain tumors.
What could go wrong
This is a very early, small phase 1 trial with only 17 children. The main goal is safety, not yet proof of effectiveness, and the drugs may cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CENTRAL NERVOUS SYSTEM TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

central nervous system cancer central nervous system neoplasm diffuse intrinsic pontine glioma neoplasm primary brain neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CENTRAL NERVOUS SYSTEM TUMORS

Contacts and locations

Locations

  • CHU Angers - Hôpital Hôtel Dieu - Service de Cancérologie Pédiatrique

    Angers, France

  • CHU Sainte-Justine

    Montreal, Canada

  • Hôpital de la Timone

    Marseille, France

  • Institut Curie - Centre de Lutte Contre le Cancer (CLCC) de Paris

    Paris, France

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea

  • The Hospital for Sick Children

    Toronto, Canada

  • Universitaetsklinikum Hamburg Eppendorf

    Hamburg, Germany

  • Universitaetsklinikum Muenster

    Münster, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.